InvestSMART

The article you are trying to access does not exist, however, here are some articles you may be interested in.

Vitrafy Life Sciences Limited (ASX: VFY) - Announcements

- Current share price for VFY : $3.500

ASX company news and announcements for Vitrafy Life Sciences Limited (VFY) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Vitrafy Life Sciences Limited (VFY) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Vitrafy Life Sciences Limited (VFY), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Vitrafy Life Sciences Limited (VFY)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$218 Q4 FY26 Quarterly Activities Report and Appendix 4C 29 Jul 2026 8:29AM $3.090 $3.500 risen by 13.27%
$218 Vitrafy enters a partnership with Hoxworth Blood Center 23 Jul 2026 8:29AM $2.810 $3.500 risen by 24.56%
$218 Application for quotation of securities - VFY 22 Jul 2026 8:26AM $2.810 $3.500 risen by 24.56%
$218 Notification of cessation of securities - VFY 13 Jul 2026 11:43AM $2.900 $3.500 risen by 20.69%
$218 Application for quotation of securities - VFY 10 Jul 2026 9:05AM $3.010 $3.500 risen by 16.28%
$218 Change of Director's Interest Notice - Correction 9 Jul 2026 9:31AM $2.960 $3.500 risen by 18.24%
$218 Change of Director's Interest Notices 9 Jul 2026 8:53AM $2.960 $3.500 risen by 18.24%
$218 Application for quotation of securities - VFY 9 Jul 2026 8:21AM $2.960 $3.500 risen by 18.24%
$218 Expiry of Voluntary Escrow Restrictions 8 Jul 2026 10:19AM $2.950 $3.500 risen by 18.64%
$218 Results of Oversubscribed Share Purchase Plan 8 Jul 2026 8:25AM $3.010 $3.500 risen by 16.28%
$218 Vitrafy Share Purchase Plan Opens - SPP Offer Booklet 19 Jun 2026 8:20AM $2.760 $3.500 risen by 26.81%
$218 Cleansing Notice 18 Jun 2026 8:22AM $2.800 $3.500 risen by 25%
$218 Application for quotation of securities - VFY 18 Jun 2026 8:22AM $2.800 $3.500 risen by 25%
$218 Proposed issue of securities - VFY 12 Jun 2026 9:33AM $3.800 $3.500 fallen by 7.89%
$218 Vitrafy Equity Raising Presentation 12 Jun 2026 9:33AM $3.800 $3.500 fallen by 7.89%
$218 Vitrafy Placement Completion and SPP Announcement 12 Jun 2026 9:32AM $3.800 $3.500 fallen by 7.89%
$218 Trading Halt 10 Jun 2026 8:32AM $3.800 $3.500 fallen by 7.89%
$218 Vitrafy Investor Presentation 3 Jun 2026 8:20AM $2.790 $3.500 risen by 25.45%
$218 Vitrafy enters a partnership with Vitalant Innovation Center 2 Jun 2026 10:08AM $2.660 $3.500 risen by 31.58%
$218 Phase 2 USAISR Platelet Results Investor Briefing 22 May 2026 8:23AM $2.340 $3.500 risen by 49.57%
$218 Phase 2 USAISR Platelet Results Investor Presentation 22 May 2026 8:23AM $2.340 $3.500 risen by 49.57%
$218 Final US Army Phase 2 Platelet Results 22 May 2026 8:20AM $2.340 $3.500 risen by 49.57%
$218 Quarterly Investor Briefing Presentation 28 Apr 2026 8:22AM $1.990 $3.500 risen by 75.88%
$218 Q3 FY26 Quarterly Activities Report and Appendix 4C 28 Apr 2026 8:21AM $1.990 $3.500 risen by 75.88%
$218 Vitrafy Q3 FY26 Investor Briefing 23 Apr 2026 4:27PM $1.895 $3.500 risen by 84.70%

1 - 25 of 112 results

Page 1 of 5

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.